Management of inflammatory bowel disease in France: A nationwide survey among private gastroenterologists

Digestive and Liver Disease

Volumn 46, Issue 8, 2014, Pages 675-681

  Duchesne, Charlène ^a   Faure, Patrick ^b   Kohler, François ^a   Pingannaud, Marie Pierre ^c   Bonnaud, Guillaume ^d   Devulder, Franck ^e   Abramowitz, Laurent ^f   Boustière, Christian ^c   Peyrin Biroulet, Laurent ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b Clinique Saint Jean Languedoc   (France)

^c SPI EAO Laboratory Faculty of Medicine ^*  (France)

^d Department of Hepato Gastroenterology Clinic des Cèdres   (France)

^e Groupe Courlancy   (France)

^f BICHAT HOSPITAL   (France)

Author keywords

Inflammatory bowel disease; Management; Private practice

Indexed keywords

TUMOR NECROSIS FACTOR INHIBITOR; ADALIMUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CANCER SCREENING; CHROMOENDOSCOPY; COLONOSCOPY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DISEASE SEVERITY; FEMALE; FRANCE; GASTROENTEROLOGIST; HEALTH SURVEY; HOSPITALIZATION; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; BIOPSY; CLINICAL PRACTICE; COLITIS, ULCERATIVE; GASTROENTEROLOGY; HEALTH CARE SURVEY; NUCLEAR MAGNETIC RESONANCE IMAGING; SEVERITY OF ILLNESS INDEX;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOPSY; COLITIS, ULCERATIVE; COLONOSCOPY; CROHN DISEASE; FEMALE; FRANCE; GASTROENTEROLOGY; HEALTH CARE SURVEYS; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904753134     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.04.004     Document Type: Article

References (41)

1. Peyrin-Biroulet L., Cieza A., Sandborn W.J., et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2012, 61:241-247.
2. Peyrin-Biroulet L., Loftus E.V., Colombel J.-F., et al. The natural history of adult Crohn's disease in population-based cohorts. American Journal of Gastroenterology 2010, 105:289-297.
3. Thia K.T., Sandborn W.J., Harmsen W.S., et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010, 139:1147-1155.
4. Peyrin-Biroulet L., Harmsen W.S., Tremaine W.J., et al. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). American Journal of Gastroenterology 2012, 107:1693-1701.
5. Samuel S., Ingle S.B., Dhillon S., et al. Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflammatory Bowel Diseases 2013, 19:1858-1866.
6. Williet N., Pillot C., Oussalah A., et al. Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Inflammatory Bowel Diseases 2012, 18:1641-1646.
7. Jess T., Rungoe C., Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clinical Gastroenterology and Hepatology 2012, 10:639-645.
8. Jess T., Gamborg M., Matzen P., et al. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. American Journal of Gastroenterology 2005, 100:2724-2729.
9. Peyrin-Biroulet L., Ferrante M., Magro F., et al. Results from the 2nd Scientific Workshop of the ECCO, I: impact of mucosal healing on the course of inflammatory bowel disease. Journal of Crohn's and Colitis 2011, 5:477-483.
10. Panes J., Bouhnik Y., Reinisch W., et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. Journal of Crohn's and Colitis 2013, 7:556-585.
11. Esser D., Cornillie F., Diamond R.H., et al. On the updated ECCO consensus guidelines for medical management of Crohn's disease. Journal of Crohn's and Colitis 2011, 5:165-166.
12. Rutgeerts P., Assche G., Van Sandborn W.J., et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012, 142. 1102-11.e2.
13. Sandborn W.J., Feagan B.G., Marano C., et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014, 146. 96-109.e1.
14. Nerich V., Monnet E., Etienne A., et al. Geographical variations of inflammatory bowel disease in France: a study based on national health insurance data. Inflammatory Bowel Diseases 2006, 12:218-226.
15. Gower-Rousseau C., Vasseur F., Fumery M., et al. Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). Digestive and Liver Disease 2013, 45:89-94.
16. Bernstein C.N., Loftus E.V., Ng S.C., et al. Hospitalisations and surgery in Crohn's disease. Gut 2012, 61:622-629.
17. Cosnes J., Nion-Larmurier I., Afchain P., et al. Gender differences in the response of colitis to smoking. Clinical Gastroenterology and Hepatology 2004, 2:41-48.
18. Lakatos L., Mester G., Erdelyi Z., et al. Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001. World Journal of Gastroenterology 2004, 10:404-409.
19. Chouraki V., Savoye G., Dauchet L., et al. The changing pattern of Crohn's disease incidence in northern France: a continuing increase in the 10- to 19-year-old age bracket (1988-2007). Alimentary Pharmacology and Therapeutics 2011, 33:1133-1142.
20. Henriksen M., Jahnsen J., Lygren I., et al. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scandinavian Journal of Gastroenterology 2007, 42:602-610.
21. Beaugerie L., Seksik P., Nion-Larmurier I., et al. Predictors of Crohn's disease. Gastroenterology 2006, 130:650-656.
22. Solberg I.C., Vatn M.H., Høie O., et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clinical Gastroenterology and Hepatology 2007, 5:1430-1438.
23. Zallot C., Peyrin-Biroulet L. Clinical risk factors for complicated disease: how reliable are they?. Digestive Diseases 2012, 30(Suppl. 3):67-72.
24. Lapidus A. Crohn's disease in Stockholm County during 1990-2001: an epidemiological update. World Journal of Gastroenterology 2006, 12:75-81.
25. Tang L.Y., Rawsthorne P., Bernstein C.N. Are perineal and luminal fistulas associated in Crohn's disease? A population-based study. Clinical Gastroenterology and Hepatology 2006, 4:1130-1134.
26. Ramadas A.V., Gunesh S., Thomas G.A.O., et al. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010, 59:1200-1206.
27. Ford A.C., Kane S.V., Khan K.J., et al. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. American Journal of Gastroenterology 2011, 106:617-629.
28. Peyrin-Biroulet L., Oussalah A., Williet N., et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011, 60:930-936.
29. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine 2010, 362:1383-1395.
30. Panaccione R., Ghosh S., Middleton S. Infliximab, azathioprine, or infliximab+azathioprine for treatment of moderate to severe ulcerative colitis: the UC SUCCESS trial. ECCO 2011, A13.
31. D'Haens G., Baert F., Assche G.van, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
32. Deepak P., Sifuentes H., Sherid M., et al. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. American Journal of Gastroenterology 2013, 108:99-105.
33. Prefontaine E., Macdonald J.K., Sutherland L.R. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2010, CD000545.
34. Bokemeyer B., Hardt J., Hüppe D., et al. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry. Journal of Crohn's and Colitis 2013, 7:355-368.
35. Schoepfer A.M., Vavricka S., Zahnd-Straumann N., et al. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. Journal of Crohn's and Colitis 2012, 6:412-418.
36. Dignass A., Assche G.Van, Lindsay J.O., et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. Journal of Crohn's and Colitis 2010, 4:28-62.
37. Peyrin-Biroulet L., Bonnaud G., Bourreille A., et al. Recommendations endoscopy in inflammatory bowel disease: recommendations from the IBD Committee of the French Society of Digestive Endoscopy (SFED). Endoscopy 2013, 45:936-943.
38. Parente F., Greco S., Molteni M., et al. Role of early ultrasound in detecting inflammatory intestinal disorders and identifying their anatomical location within the bowel. Alimentary Pharmacology and Therapeutics 2003, 18:1009-1016.
39. Israeli E., Ying S., Henderson B., et al. The impact of abdominal computed tomography in a tertiary referral centre emergency department on the management of patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 2013, 38:513-521.
40. Beaugerie L., Brousse N., Bouvier A.M., et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009, 374:1617-1625.
41. Feuerstein J.D., Akbari M., Gifford A.E., et al. Systematic review: the quality of the scientific evidence and conflicts of interest in international inflammatory bowel disease practice guidelines. Alimentary Pharmacology and Therapeutics 2013, 37:937-946.